• 1
    Chugh SS, Reinier K, Teodorescu C, et al. Epidemiology of sudden cardiac death: Clinical and research implications. Prog Cardiovasc Dis 2008;51:213228.
  • 2
    Fishman GI, Chugh SS, Dimarco JP, et al. Sudden cardiac death prediction and prevention: Report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010;122:23352348.
  • 3
    Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: Multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004;44:12681275.
  • 4
    Nichol G, Thomas E, Callaway CW, et al. Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA 2008;300:14231431.
  • 5
    Buxton AE, Lee KL, Hafley GE, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: Lessons from the MUSTT study. J Am Coll Cardiol 2007;50:11501157.
  • 6
    Chugh SS, Uy-Evanado A, Teodorescu C, et al. Women have a lower prevalence of structural heart disease as a precursor to sudden cardiac arrest: The Ore-SUDS (Oregon Sudden Unexpected Death Study). J Am Coll Cardiol 2009;54:20062011.
  • 7
    Haider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998;32:14541459.
  • 8
    Schatzkin A, Cupples LA, Heeren T, et al. Sudden death in the Framingham Heart Study. Differences in incidence and risk factors by sex and coronary disease status. Am J Epidemiol 1984;120:888899.
  • 9
    Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general population: The Tromso Study. Eur Heart J 1999;20:429438.
  • 10
    Wolk R. Arrhythmogenic mechanisms in left ventricular hypertrophy. Europace 2000;2:216223.
  • 11
    Cooklin M, Wallis WR, Sheridan DJ, et al. Changes in cell-to-cell electrical coupling associated with left ventricular hypertrophy. Circ Res 1997;80:765771.
  • 12
    McIntyre H, Fry CH. Abnormal action potential conduction in isolated human hypertrophied left ventricular myocardium. J Cardiovasc Electrophysiol 1997;8:887894.
  • 13
    Winterton SJ, Turner MA, O'Gorman DJ, et al. Hypertrophy causes delayed conduction in human and guinea pig myocardium: Accentuation during ischaemic perfusion. Cardiovasc Res 1994;28:4754.
  • 14
    Rials SJ, Wu Y, Ford N, et al. Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart. Circulation 1995;91:426430.
  • 15
    Oikarinen L, Nieminen MS, Viitasalo M, et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens 2001;19:18831891.
  • 16
    Oikarinen L, Nieminen MS, Viitasalo M, et al. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: The Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2004;43:10291034.
  • 17
    Chugh SS, Reinier K, Singh T, et al. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: The Oregon Sudden Unexpected Death Study. Circulation 2009;119:663670.
  • 18
    Adabag AS, Peterson G, Apple FS, et al. Etiology of sudden death in the community: Results of anatomical, metabolic, and genetic evaluation. Am Heart J 2010;159:3339.
  • 19
    Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:14401463.
  • 20
    Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986;57:450458.
  • 21
    Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984;4:12221230.
  • 22
    Rosa EC, Moyses VA, Sesso RC, et al. Left ventricular hypertrophy evaluation in obese hypertensive patients: Effect of left ventricular mass index criteria. Arq Bras Cardiol 2002;78:341351.
  • 23
    Perkiomaki JS, Koistinen MJ, Yli-Mayry S, et al. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 1995;26:174179.
  • 24
    Bazett HC. An analysis of the time-relations of electrocardiorams. Heart 1920;7:353357.
  • 25
    Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969;71:89105.
  • 26
    Kreger BE, Cupples LA, Kannel WB. The electrocardiogram in prediction of sudden death: Framingham Study experience. Am Heart J 1987;113:377382.
  • 27
    Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:15611566.
  • 28
    Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: The LIFE Study. Circulation 2007;116:700765.
  • 29
    Morin DP, Oikarinen L, Viitasalo M, et al. QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: The LIFE study. Eur Heart J 2009;30:29082914.
  • 30
    Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction. 2. Indications for temporary and permanent pacemaker insertion. Circulation 1978;58:689699.